Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
about
Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyondPrognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern cooperative oncology group E2303.Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.AKT regulates NPM dependent ARF localization and p53mut stability in tumors.N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in erlotinib-resistant lung cancer cell linesPrevention of tumor growth driven by PIK3CA and HPV oncogenes by targeting mTOR signaling with metformin in oral squamous carcinomas expressing OCT3.Characterization of STAT3 expression, signaling and inhibition in feline oral squamous cell carcinomaPresent and Future of EGFR Inhibitors for Head and Neck Squamous Cell CancerMEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.Cetuximab enhanced the efficacy of chemotherapeutic agent in ABCB1/P-glycoprotein-overexpressing cancer cells.AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.Telomeric repeat-binding factor 2: a marker for survival and anti-EGFR efficacy in oral carcinomaDeguelin Potentiates Apoptotic Activity of an EGFR Tyrosine Kinase Inhibitor (AG1478) in PIK3CA-Mutated Head and Neck Squamous Cell Carcinoma.Anti-epidermal growth factor receptor therapy in head and neck squamous cell carcinoma: focus on potential molecular mechanisms of drug resistanceThe dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models.
P2860
Q28080730-EDAE3AD1-BEC7-4B19-A104-13FE4F8E1791Q33725229-7F6B1699-F4C9-47E3-8836-C70FBA25B396Q34093266-3D209732-078D-44A3-8BDD-2B1CAE6AC67BQ34227622-0A58D82F-9DFD-4A0E-B48D-B79127A510D6Q34631703-79A9EE62-44E2-44A0-BAD5-A2EE6B115443Q35164428-2CB3F482-83D1-4854-A0B0-0CA5F9CDC0E7Q35745696-7A7FD2C0-C418-4979-BB3D-52956E822D7AQ35875753-258518A9-B605-48B8-B97D-E9C4C223CE39Q36021572-95CD9696-FF18-4A10-8DB0-6361D73D24A0Q36562186-751B8E4A-B4FA-48FF-92A4-F42379930677Q37161304-0340A67E-1F56-4B85-8DF8-A74CE242301CQ37536848-8BD840C3-E4CC-45D1-9D14-BF01FEDC7475Q37690668-D9F973BB-CB02-4875-9D3A-67941857145CQ38118934-65D345BB-DACC-493B-91C8-8C7144C2B4B3Q38995499-586EDB4A-C7BF-4040-BFA3-59783556B020
P2860
Mechanisms underlying resistance to cetuximab in the HNSCC cell line: role of AKT inhibition in bypassing this resistance.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Mechanisms underlying resistan ...... in bypassing this resistance.
@en
Mechanisms underlying resistan ...... in bypassing this resistance.
@nl
type
label
Mechanisms underlying resistan ...... in bypassing this resistance.
@en
Mechanisms underlying resistan ...... in bypassing this resistance.
@nl
prefLabel
Mechanisms underlying resistan ...... in bypassing this resistance.
@en
Mechanisms underlying resistan ...... in bypassing this resistance.
@nl
P2093
P1476
Mechanisms underlying resistan ...... n in bypassing this resistance
@en
P2093
Amélie Dewitte
Amélie Lansiaux
Claire Vautravers-Dewas
Eric Guerin
Eric Lartigau
Jean-Philippe Peyrat
Magali Rebucci
Marie-Adeline De Nuncques
Marie-Pierre Buisine
Nicolas Rezvoy
P304
P577
2011-01-01T00:00:00Z